Sagimet Biosciences (NASDAQ: SGMT - Get Free Report)'s stock had its "buy" rating reaffirmed by inve

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with

Sagimet Biosciences (NASDAQ: SGMT) said its licensed partner Ascletis reported positive 52-week resu

Sagimet Biosciences NASDAQ: SGMT said its licensed partner Ascletis reported positive 52-week result

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and ra

FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and r

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifansta

Sagimet Biosciences Inc. (NASDAQ:SGMT) reported 52-week data from a Phase 3 trial evaluating denifan

Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $1

What happened Sagimet Biosciences Inc. (NASDAQ: SGMT) said denifanstat produced a 57.8% treatment su

Underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per shar

FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a c

Effective September 30, 2026, the Company suspended and terminated the prospectus supplement (the &#

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel

In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne rece

FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a c

Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and

Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and i

Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Ove

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SG

Biotechnology investing is a strange corner of the market. A company can own a drug that may even

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a c

Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus rati

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with

All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2

All clinical trial sites identified and CRO retained Patient screening expected to begin in October

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, o

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp

Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to in

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the an

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.

After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc.

https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-as

Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the anal

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lo

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel